Scarica l'app Stockscreener
5.31
3.71%
0.19
Dopo l'orario di chiusura:
5.24
-0.07
-1.32%
Precedente Chiudi:
$5.12
Aprire:
$5.07
Volume 24 ore:
1.24M
Relative Volume:
0.85
Capitalizzazione di mercato:
$147.91M
Reddito:
$675.00K
Utile/perdita netta:
$-39.95M
Rapporto P/E:
-2.5822
EPS:
-2.0564
Flusso di cassa netto:
$-28.67M
1 W Prestazione:
+0.19%
1M Prestazione:
+5.78%
6M Prestazione:
-23.60%
1 anno Prestazione:
+23.78%
Intervallo 1D:
$5.04
$5.62
Intervallo di 1 settimana:
$5.01
$5.62
Portata 52W:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.31 | 142.62M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
UNCY Class Action Notice: Robbins LLP Reminds Investors of - GlobeNewswire
Kaplan Fox Encourages Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to Contact the Firm to Learn About Their Legal Rights - NewMediaWire
UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities LawsuitContact SueWallSt - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors - GlobeNewswire
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Law Offices of Frank R. Cruz Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
UNCY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (NASDAQ: UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 - 巴士的報
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact Levi & Korsinsky - PR Newswire
UNCY SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
UNCY Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Unicycive Therapeutics, Inc. - Morningstar
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Unicycive faces class action over undisclosed F... - Pluang
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders W - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Unicycive - GlobeNewswire
Deadline Soon: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - FinancialContent
Class action lawsuit filed against Unicycive Th... - Pluang
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
UNCY Stock On Track For Worst Day In About A Year Ahead Of FDA Decision On Lead Drug - Stocktwits
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
UNCY INVESTOR ALERT: Securities Class Action Filed Against Unicycive Therapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
DEADLINE ALERT for YSS, HIMS, and UNCY: The Law Offices of - GlobeNewswire
UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm - lincolnjournal.com
Law Offices of Howard G. Smith Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders To Inquire About Securities Fraud Class Action - FinancialContent
Robbins LLP Informs Investors of the Unicycive Therapeutics, Inc. Securities Class Action - Business Wire
UNCY CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit On Behalf Of Unicycive Therapeutics, Inc. Investors - The Daily Tribune News
Unicycive Therapeutics stock trades near USD 5.26 - ad-hoc-news.de
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Unicycive Therapeutics stock faces pressure ahead of key FDA decision - ad-hoc-news.de
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research - MarketBeat
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Raises Target Price to $15 - Moomoo
UNCY Maintained by Benchmark -- Price Target Raised to $15.00 - GuruFocus
Benchmark raises Unicycive Therapeutics price target on FDA progress By Investing.com - Investing.com Canada
UNCY Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia - Bitget
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - TechFinancials
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
UNICYCIVE THERAPEUTICS INC : GUGGENHEIM CUTS TARGET PRICE TO $25 FROM $37 - webull.com
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):